Jazz Pharmaceuticals plc — Director's Dealing 2017

Nov 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2017-11-17

Reporting Person: McGill Iain (SVP, Europe & Rest of World)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-17	Ordinary Shares	M	8000	$46.83	Acquired	28383	Direct
2017-11-17	Ordinary Shares	S	8000	$133.4197	Disposed	20383	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-17	Non-Qualified Stock Option (right to buy)	$46.83	M	8000	Disposed	2022-08-08	Ordinary Shares (8000)	Direct

Footnotes

F1: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $132.95 to $133.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: This non-qualified stock option was granted on August 9, 2012 and vested over a period four years from date of grant. The options were fully vested as of August 9, 2016.